Skip to main content
Fig. 7 | Breast Cancer Research

Fig. 7

From: siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression

Fig. 7

Intratumoral administration ofITGA11siRNA prolongs survival of mice with drug-resistant breast cancer

(A) Tumor volume after intratumoral treatment with siRNA or GSK-126 at day 1, 4, 8, and 11, marked by arrows. Tumor volume was measured twice per week and significant differences in tumor volume compared to siNT are indicated at day 14. *p < 0.05 compared to Mock or siNT-transfected group. (B) Bioluminescent imaging by luciferase in TAMR xenografts at 3 days after the last treatment with siRNA or drug. D-luciferin (150 mg/kg) was injected via intraperitoneal injection in mice. At 10 min after D-luciferin injection, the converted D-luciferin was measured in the value of emitted photons. The tumor size in each group was shown by bioluminescent imaging by CCD camera. (C) Survival curves depicting the outcomes of the respective cohorts

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us